Latest Glioma Stories
Single agent NKTR-102 exceeds primary endpoint with fifty-five percent of patients achieving six-week progression-free survival and fifteen percent of patients achieving partial response
VANCOUVER, British Columbia and MENLO PARK, Calif., May 31, 2014 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI)
- Results from Phase I study of investigational oncology compound ABT-414 in patients with recurrent or unresectable glioblastoma multiforme, an aggressive type of brain cancer NORTH CHICAGO,
In Addition, Toca 511 Clinical Data to be Presented at American Society of Clinical Oncology Annual Meeting SAN DIEGO, May 22, 2014 /PRNewswire/ --
CALGARY, May 20, 2014 /PRNewswire/ - Oncolytics Biotech Inc.
30mg/m2 dose cohort had been completed; enrollment of 40mg/m2 cohort has been initiated VANCOUVER, British Columbia and MENLO PARK, Calif., May 16, 2014 /PRNewswire/ --
Wildlife Correspondent to Help Raise Awareness of 700,000 Living with a Brain Tumor Chicago, IL (PRWEB) May 06, 2014 Inspired by his daughter’s courageous
VISIUS intraoperative MRI significantly enhances amount of complete resection in brain tumors and leads to better patient outcomes MINNEAPOLIS, April 17, 2014 /PRNewswire/ -
CALGARY, April 11, 2014 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC) (NASDAQ:ONCY) today announced that Dr.
Results Continue to Show Safety and Promising Survival; Program to Advance into a Randomized, Controlled Trial SAN DIEGO, April 10, 2014 /PRNewswire/ --
- In medieval musical notation, a sign or neume denoting a shake or trill.